You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
With nearly $100 million in new investments since last year, the San Francisco-based informatics firm looks to ramp up its precision oncology partnerships.
Vikor has invested an undisclosed amount to help the startup commercialize a direct-to-consumer service that includes genomic risk testing and liquid biopsy cancer screening.
Spun out of the Glasgow Precision Oncology Laboratory, Gabriel wants targeted sequencing to become the norm for all somatic cancer patients.
With its liquid biopsy test FDA approved and monitoring and screening offerings poised for launch, the firm is turning its attention to tumor tissue testing.
Tempus has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new cancer biomarkers.
Ancestry will focus more on family history and genetic genealogy, and called the move a "strategic but difficult decision."
The African health technology company 54gene is eager for partnerships with researchers and biopharmaceutical companies alike.
The researchers identified molecular subtypes of head and neck cancer that could be susceptible to CDK inhibitor, anti-EGFR antibody, or immunotherapy treatments.
Wired speaks with National Human Genomics Research Institute's Eric Green about the Human Genome Project.
A multi-ancestry genome-wide association study meta-analysis uncovered 86 genetic loci associated with prostate cancer risk that researchers bundled into a genetic risk score.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.